TechInvest News

Audeara (ASX: AUA) Hits Record Q1 FY25 Revenue with Strong Technology Growth, Expands into Asia

Written by Staff Writer | Oct 28, 2024 10:51:02 PM
Audeara Limited (ASX: AUA) has started FY25 with impressive momentum, posting record revenue and achieving strategic milestones that spotlight the company’s technology-driven expansion in hearing health solutions. For the quarter ending 30 September 2024, Audeara reported revenue of $1.42 million, a staggering 230% increase year-on-year, fuelled primarily by robust growth in its technology division. Cash receipts reached $1.2 million, marking a 53% year-on-year increase, as the AUA Technology business continues to drive top-line growth and profitability.
 

Financial Highlights: Technology Division Boosts Revenue

Audeara’s technology licensing agreements, particularly with global music company Avedis Zildjian, were significant contributors to the quarter’s record performance. The AUA Technology division, now Audeara’s primary revenue driver for two consecutive quarters, has seen a steady rise in demand as its custom audio technology gains traction among international clients. Zildjian’s Perfect Tune headphones, which utilise Audeara’s hearing-specific audio technology, continued to generate strong sales, and Zildjian placed an additional cash deposit post-quarter to secure long-lead components for future orders.

“The September quarter represented another period of strong execution with respect to our stated growth strategy, highlighted by ongoing momentum for the group’s well-established and fast-growing AUA Technology division,” said CEO Dr James Fielding. “This progress was achieved alongside consistent trend improvements in key financial metrics, including cash receipts and net operating cash flows.”

Strategic Asian Market Expansion

Audeara is also advancing its footprint in Asia, where its technology division is positioned to meet rising demand for hearing solutions. A standout achievement was the binding Letter of Intent (LOI) with Eastech Limited, a Taiwan Stock Exchange-listed company, to enter the Chinese hearing aid market. Eastech’s capabilities in certified medical device manufacturing align well with Audeara’s proprietary technology, setting up a promising entry into a market with an estimated 426 million people affected by hearing loss. Under the agreement, Eastech will use Audeara’s technology for devices approved by China’s National Medical Products Administration (NMPA), creating a high-potential revenue stream within Asia’s rapidly growing healthcare sector.

The company also secured a $570,000 purchase order from Clinico Inc., Taiwan’s largest hearing aid retailer, for the development of Clinico-branded hearing earbuds using Audeara’s technology. This deal, which includes an upfront deposit of $180,000, provides Audeara with valuable brand presence in Taiwan and China and marks an exciting step in its broader strategy to bring hearing health products to a larger global audience.

Financial Efficiency and Cash Position

Audeara’s capital efficiency initiatives yielded a notable improvement in operating cash flow, with net cash outflows reduced by 70% quarter-on-quarter to $280,000. Cash holdings at quarter’s end stood at $920,000, and an additional R&D tax rebate of $680,000 is expected to further support the company’s expansion efforts.

Positioned for Sustained Growth

Audeara’s Q1 FY25 achievements affirm its technology-led growth strategy and the company’s ability to secure and expand revenue streams through targeted market entry and strategic partnerships. As Audeara’s AUA Technology division expands into more markets, especially within Asia, the company is increasingly positioned to capture demand in the hearing health sector. With strong foundations in both financial and technological growth, Audeara is well-prepared to build on these gains in the coming quarters.